en · de · es · fr · pt
methods-notes.peptides4088.com › News › Thymosin Beta-4 Fragment Identity — Practical Notes

Thymosin Beta-4 Fragment Identity — Practical Notes

By Editorial Desk · published 2026-05-07 · last reviewed 2026-05-26 · News

Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2026-05-26. Numbers and descriptions here follow the published literature rather than marketing material.

Thymosin Beta-4 Fragment Identity

Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

TB-500 Identity and Naming Background

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Tb-500 at a glance

PropertyValueNotes
Molecular massApproximately 4963 Da for full-length thymosin beta-4Value applies to the parent protein; fragment products may differ
AppearanceWhite to off-white lyophilized powderTypical form of supplied synthetic peptide
SolubilityFreely soluble in waterPolar peptide; dissolves readily in aqueous buffer
Storage of dry powder−20 °C, desiccated, protected from lightStandard laboratory practice for peptides
Typical detection methodLiquid chromatography–tandem mass spectrometryUsed in purity testing and anti-doping analysis

Identity and Research Background

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Related pages on this site

Identity and Physical Form

The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.

The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.

Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.

TB-500 Identity and Chemical Background

TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.

Identity And Naming Background

TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.

Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.

Supporting material

, the spreading slows down thus useful to set a prediction on the short-term trends. Also, it can be used to directly calculate the threshold population of vaccination/immunization for the herd immunity stage by setting

In 1795, observing the toll that poor nutrition took on his men, Napoleon announced a prize of 12,000 francs to anyone who could improve upon the prevailing food preservation methods of the time. In 1810, Nicholas Appert claimed the prize after devising a method of preserving food in which tightly sealing food inside a bottle and maintaining it at high temperature for certain period of time made the food safe for consumption until opening, using glass jars sealed with corks and boiling water. A trial in which food preserved by this method was sent overseas with French troops succeeded. Appert was given the money on condition that he make his discovery public, and duly published The Art of Preserving Animal and Vegetable Substances. The French Navy began using his methods. The Grande Armée experimented with issuing canned foods to its soldiers. However, the slow process of canning and the even slower development and transport stages prevented large amounts from being shipped across the French Empire, and the wars ended before the process was perfected. A major difficulty that presented itself was the use of glass, which was heavy, fragile, and could explode under internal pressure. Appert's work was improved upon by Philippe de Girard in 1811, when he pioneered a method of preserving food in metal cans. It was patented in Britain on his behalf by Peter Durand, who took the credit as its inventor. Girard, a Frenchman, preferred the entrepreneurial environment of Britain, but could not have taken out a patent in a country with which his own country was at war with.

=== Enhanced oil recovery and carbon capture and storage === Supercritical carbon dioxide is used to enhance oil recovery in mature oil fields. At the same time, there is the possibility of using "clean coal technology" to combine enhanced recovery methods with carbon sequestration. The CO2 is separated from other flue gases, compressed to the supercritical state, and injected into geological storage, possibly into existing oil fields to improve yields. At present, only schemes isolating fossil CO2 from natural gas actually use carbon storage, (e.g., Sleipner gas field), but there are many plans for future CCS schemes involving pre- or post-combustion CO2. There is also the possibility to reduce the amount of CO2 in the atmosphere by using biomass to generate power and sequestering the CO2 produced.

Sources: en.wikipedia.org

Supporting material

== Alternative PDRN sources == Variability in biological sources and production methods have shown to contribute to variations in biological activity of PDRN, more specifically with celullar pathways activation. As a results, alternative sources of PDRN are an ongoing research field that aims to better identify alternative sources with their associated effects. In addition to the standard animal-derived PDRN, there are other alternatives like plant, microbial and human-derived PDRN that have been studied to improve sustainbility and efficiency depending on the tissue model. These alternative sources gained more interest since low-molecular weight PDRN is related to better bioavailability, celullar uptake and skin penetration. Most alternative-source preparations contain DNA fragments with lower molecular weight than the animal-derived PDRN.

The Botswana Meat Commission (BMC) is a non-profit body which was established by the government of the newly independent Botswana in 1965. Its main functions are the buying, slaughtering, processing, and marketing of all beef and beef products within Botswana for sale in local and international markets.

Microbubbles are bubbles smaller than one hundredth of a millimetre in diameter, but larger than one micrometre. They have widespread application in industry, medicine, life science, and food technology. The composition of the bubble shell and filling material determine important design features such as buoyancy, crush strength, thermal conductivity, and acoustic properties. They are used in medical diagnostics as a contrast agent for ultrasound imaging. The gas-filled microbubbles, typically air or perfluorocarbon, oscillate, and vibrate if a sonic energy field is applied and may reflect ultrasound waves. This distinguishes the microbubbles from surrounding tissues. Because gas bubbles in liquid lack stability and would therefore quickly dissolve, microbubbles are typically encapsulated by shells. The shell is made from elastic, viscoelastic, or viscous material. Common shell materials are lipid, albumin, and protein. Materials having a hydrophilic outer layer to interact with the bloodstream and a hydrophobic inner layer to house the gas molecules are thermodynamically stable. Air, sulfur hexafluoride, and perfluorocarbon gases all can serve as the composition of the microbubble interior. Microbubbles with one or more incompressible liquid or solid cores surrounded by gas are referred to as microscopic or endoskeletal antibubbles. For increased stability and persistence in the bloodstream, gases with high molecular weight as well as low solubility in the blood are attractive candidates for microbubble gas cores.

== Prevention == There is little or no data to support the concept that activity adjustment prevents carpal tunnel syndrome. The evidence for using a wrist rest at a computer keyboard is debated. There is also little research supporting that ergonomics is related to carpal tunnel syndrome. Given that biological factors, such as genetic predisposition and anthropometric features, are more strongly associated with carpal tunnel syndrome than occupational/environmental factors such as hand use, CTS may not be prevented by activity modifications. Some claim that worksite modifications such as switching from a QWERTY computer keyboard layout to Dvorak are helpful, but meta-analyses of the available studies note limited supported evidence.

Sources: en.wikipedia.org

Supporting material

== Services == Flagler Global Logistics offers consolidation and deconsolidation, multimodal transportation, warehouse management, Foreign Trade Zone, and dry and refrigerated cargo services, as well as commercial real estate development. FGL is the only company with direct connectivity to PortMiami, Port Everglades, and Miami International Airport. FGL currently operates or is developing, six Class-A logistics and distribution facilities throughout Florida. In total, FGL's assets include more than 1 million square feet of move-in ready, Class-A warehouse and distribution space, as well as more than 2,000 gross acres of land holdings throughout Florida that could accommodate nearly 24 million square feet of industrial development. Flagler Global Logistics flagship multimodal distribution complex—South Florida Logistics Center—is located adjacent to the Miami International Airport, with exclusive rail connectivity via the Florida East Coast Railway to South Florida's busiest ports—PortMiami and Port Everglades. The more-than-200-acre South Florida Logistics Center opened in November 2013. Its centerpiece is Flagler Global Logistics’ cold-chain management facility. When fully built out, the center will consist up to 2 million square feet of industrial space. South Florida Logistics Center is an approved magnet site for Foreign Trade Zone No. 281. Tenants include Goodyear and the Flying Food Group.

To overcome the dust issues and poor flowability of the powder, a new generation of spray dryers called multiple effect spray dryers have been developed. Instead of drying the liquid in one stage, drying is done through two steps: the first at the top (as per single effect) and the second with an integrated static bed at the bottom of the chamber. The bed provides a humid environment which causes smaller particles to clump, producing more uniform particle sizes, usually within the range of 100 to 300 μm. These powders are free-flowing due to the larger particle size. The fine powders generated by the first stage drying can be recycled in continuous flow either at the top of the chamber (around the sprayed liquid) or at the bottom, inside the integrated fluidized bed. The drying of the powder can be finalized on an external vibrating fluidized bed. The hot drying gas can be passed in as a co-current, same direction as sprayed liquid atomizer, or counter-current, where the hot air flows against the flow from the atomizer. With co-current flow, particles spend less time in the system and the particle separator (typically a cyclone device). With counter-current flow, particles spend more time in the system and is usually paired with a fluidized bed system. Co-current flow generally allows the system to operate more efficiently. Alternatives to spray dryers are:

Biosecurity refers to measures aimed at preventing the introduction and/or spread of harmful organisms (e.g., viruses, bacteria, etc.) to animals and plants to mitigate the risk of transmission of infectious disease. In agriculture, these measures are aimed at protecting food crops and livestock from pests, invasive species, and other organisms not conducive to the welfare of the human population. The term includes biological threats to people, such as pandemic diseases and bioterrorism. The definition has sometimes been broadened to embrace other concepts, and it is used for different purposes in different contexts. The most common category of biosecurity policies is quarantine measures adopted to counteract the spread of disease and, when applied as part of border control, primarily focus on mitigating the entry of infected individuals, plants, or animals into a country. Other aspects of biosecurity related to border control include mandatory vaccination policies for inbound travellers and measures to curtail the risk posed by bioterrorism or invasive species. Quarantine measures are frequently implemented regarding the mobility of animals, including both pets and livestock. Notably, to reduce the risk of introducing rabies from continental Europe, the United Kingdom used to require that dogs and most other animals introduced into the country spend six months in quarantine at an HM Customs and Excise pound.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.

Has any regulator approved TB-500 for medical use?

No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.

Why does TB-500 appear in anti-doping literature?

It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

Network